Rama Suresh MD

Oncology•Saint Louis, MO

Breast Cancer, Gastrointestinal Cancer

Associate Professor, Medical Oncology, Washington University School of Medicine Medical Director, Siteman Cancer Center West County

Join to View Full Profile

10 Barnes West Dr# DvSaint Louis, MO 63141
Phone+1 800-647-2098
Fax+1 314-362-3192

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2002 - 2004
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1995 - 1998
Madras Medical CollegeClass of 1993

Certifications & Licensure

IL State Medical License 2021 - 2026
MO State Medical License 1998 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Castle Connolly Top Doctor 2021-2022
Best Doctor US News and World Report 2015-2022
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer Start of enrollment: 2011 May 10
ACTIVE_NOT_RECRUITING
PHASE1
Registry Study - Whipple at the Splenic Artery Start of enrollment: 2010 Sep 20
Completed
FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Start of enrollment: 2012 Apr 01
Completed
Phase 1
Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma Start of enrollment: 2009 Dec 16
Completed
Phase 1
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11
Completed
Phase 2
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies Start of enrollment: 2013 May 07
Completed
Phase 1
Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Start of enrollment: 2014 Apr 01
Withdrawn
Phase 2
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells Start of enrollment: 2013 Dec 19
Terminated
Phase 2
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2013 May 03
Terminated
Phase 1, Phase 2
Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer Start of enrollment: 2013 Nov 08
Completed
Phase 2
Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer Start of enrollment: 2014 Aug 01
Withdrawn
Phase 2
Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery Start of enrollment: 2014 Jun 01
Terminated
Phase 1
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity Start of enrollment: 2014 Jul 07
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Neoadjuvant BMS-813160, nivolumab, gemcitabine and nab-paclitaxel for patients with pancreatic cancer.
Patrick M Grierson, Crystal Wolf, Rama Suresh, Andrea Wang-Gillam, Benjamin R Tan
Clinical Cancer Research. 2025-03-24
Detection of circulating tumor DNA using a tissue-free epigenomic assay is a highly prognostic biomarker in early-stage triple negative breast cancer.
Foluso O Ademuyiwa, Cynthia X Ma, Katherine Weilbaecher, Rama Suresh, Lindsay L Peterson
Clinical Cancer Research. 2025-03-21
3 citations
Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients.
Xiuli Zhang, S Peter Goedegebuure, Michael Y Chen, Rashmi Mishra, Felicia Zhang
Genome Medicine. 2024-11-14

Professional Memberships

American College of Physicians - ACP
Member
American Society of Clinical Oncology - ASCO
Member